20 research outputs found
Both lamin A and lamin C mutations cause lamina instability as well as loss of internal nuclear lamin organization.
We have applied the fluorescence loss of intensity after photobleaching (FLIP) technique to study the molecular dynamics and organization of nuclear lamin proteins in cell lines stably transfected with green fluorescent protein (GFP)-tagged A-type lamin cDNA. Normal lamin A and C proteins show abundant decoration of the inner layer of the nuclear membrane, the nuclear lamina, and a generally diffuse localization in the nuclear interior. Bleaching studies revealed that, while the GFP-tagged lamins in the lamina were virtually immobile, the intranuclear fraction of these molecules was partially mobile. Intranuclear lamin C was significantly more mobile than intranuclear lamina A.
In search of a structural cause for the variety of inherited diseases caused by A-type lamin mutations, we have studied the molecular organization of GFP-tagged lamin A and lamin C mutants R453W and R386K, found in Emery–Dreifuss muscular dystrophy (EDMD), and lamin A and lamin C mutant R482W, found in patients with Dunnigan-type familial partial lipodystrophy (FPLD). In all mutants, a prominent increase in lamin mobility was observed, indicating loss of structural stability of lamin polymers, both at the perinuclear lamina and in the intranuclear lamin organization. While the lamin rod domain mutant showed overall increased mobility, the tail domain mutants showed mainly intranuclear destabilization, possibly as a result of loss of interaction with chromatin. Decreased stability of lamin mutant polymers was confirmed by flow cytometric analyses and immunoblotting of nuclear extracts.
Our findings suggest a loss of function of A-type lamin mutant proteins in the organization of intranuclear chromatin and predict the loss of gene regulatory function in laminopathies
Proteasome-mediated degradation of integral inner nuclear membrane protein emerin in fibroblasts lacking A-type lamins.
We previously identified and characterized a homozygous LMNA nonsense mutation leading to the absence of A-type lamins in a premature neonate who died at birth. We show here that the absence of A-type lamins is due to degradation of the aberrant mRNA transcript with a premature termination codon. In cultured fibroblasts from the subject with the homozygous LMNA nonsense mutation, there was a decreased steady-state expression of the integral inner nuclear membrane proteins emerin and nesprin-1alpha associated with their mislocalization to the bulk endoplasmic reticulum and a hyperphosphorylation of emerin. To determine if decreased emerin expression occurred post-translationally, we treated cells with a selective proteasome inhibitor and observed an increase in expression. Our results show that mislocalization of integral inner nuclear membrane proteins to the endoplasmic reticulum in human cells lacking A-type lamins leads to their degradation and provides the first evidence that their degradation is mediated by the proteasome
Effect of pathogenic mis-sense mutations in lamin A on its interaction with emerin in vivo
10.1242/jcs.00599Journal of Cell Science116143027-303
Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone
Dunnigan-type familial partial lipodystrophy (FPLD) is caused by mutations in LMNA, the gene that encodes nuclear lamins A and C. FPLD is characterized by peripheral fat loss, excess central adiposity, insulin resistance, and hyperlipidaemia, which are difficult to treat. We present our 2 years' experience of treatment with rosiglitazone in a subject with FPLD. Insulin requirement decreased significantly from 240 IU/day to 76 IU/day (range 20-240 IU/day) and serum triglyceride concentration was lowered from 13.7 +/- 14.4 mmol/l to 4.5 +/- 4.3 mmol/l and remained stable. Mean HbA(1c) prior to rosiglitazone therapy was 9.4 +/- 1.32% and decreased to 7.4 +/- 0.6% during therapy with rosiglitazone. This case demonstrates the benefits of PPARgamma-agonists on glycaemic control and dyslipidaemia in a patient with FPLD. This in turn implies that PPARgamma may play a pathophysiological role in FPLD
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Although there have been signi\ufb01cant advances in understanding the clinical and biochemical
features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of
biomarkers as prognostic indicators. This is particularly important at the time of initial diagno-
sis. Indeed, the widespread use of antimitochondrial antibody testing has led to an earlier diag-
nosis of asymptomatic PBC and it is dif\ufb01cult to predict which patients will experience a benign
versus a rapidly progressive course. To address this issue, we examined a unique population of
127 newly diagnosed patients with PBC during a 15-year period of observation that began in
January 1990. Sera from these patients were analyzed for antimitochondrial, antinuclear, and
anti\u2013smooth muscle antibodies, and immunoblotting was performed for nuclear pore complex
(NPC). The patients were then followed up longitudinally using biochemical liver function tests.
No patient was under any medical therapy for PBC at the time of the initial sera collection. Data
were analyzed based not only on the clinical features, but also the Mayo score and speci\ufb01c
outcome measures, including time to death, need for liver transplantation, and complication free
survival. Among patients with early disease, bilirubin increased to >2 mg/dL in the anti-NPC( )
patients (26% vs. 5%, P .019). Anti-NPC antibodies remained stable or slightly increased over
the period of observation. In conclusion, anti-NPC identi\ufb01es patients likely to experience an
unfavorable clinical course and more rapid disease progression